Led · Seed · Jul 2026

Sightera develops an AI-native drug discovery platform that trains generative models on proprietary datasets derived from patient-derived biological samples and organoid preclinical models. By centering human disease biology—particularly samples from individuals with advanced, therapy-resistant disease—the company aims to design small molecules based on observed biological responses rather than solely chemical properties. Its stated therapeutic focuses are oncology and fibrosis, with a lead molecular glue oncology programme moving toward preclinical candidate selection. Sightera is a spin-off of the University of Antwerp and Antwerp University Hospital (UZA) and will use its recent funding to expand its research, AI and data science teams and to strengthen strategic partnerships with pharma and biotech companies. The company plans to scale its platform and accelerate translation of its pipeline using the new capital.

Participated · Series A · May 2026

eyeo was founded to commercialise nanophotonic imaging technology developed at imec and builds the NCOS® platform that replaces conventional color filters by splitting and directing light to individual pixels. The technology is compatible with existing CMOS sensor platforms, enables ultra‑compact sub‑micron pixels, and aims to improve light sensitivity, color accuracy and image resolution. eyeo targets applications across smartphones, industrial systems, XR devices, smart cities and autonomous systems. The company reports its technology is proven, patented and validated at a commercial foundry, with tier‑one customers already engaged. Financially, the company has raised a total of €55 million to date following the €40 million Series A. Eyeo plans to use the new funding to scale commercial delivery, expand engineering, strengthen OEM partnerships and invest in next‑generation 3D‑stacked CMOS image sensors and IC/system architecture capabilities.

Led · Equity · Feb 2026

Firecell, now merged with fellow 5G specialist Accelleran, offers a single-stack private 5G solution that combines Firecell’s core network and network-management software with Accelleran’s programmable RAN, management and AI capabilities. The platform supports all FDD and TDD spectrum bands, delivers sub-millisecond latency for thousands of concurrent IoT devices, enables network slicing and mission-critical voice services, and integrates AI-driven optimisation through xApps and rApps. Designed and developed entirely in Europe, the software can be deployed on-premise to guarantee data sovereignty for ports, factories, defence sites and logistics facilities. The combined company will operate under the Firecell brand, doubling its engineering and commercial footprint with teams across France, Belgium, the UK, Germany and Poland, and active deployments in Europe, the U.S. and Asia. Management believes the unified, hardware-agnostic stack will simplify multi-site private 5G roll-outs for system integrators and accelerate industrial autonomy. The merger is supported by a €7.9 million investment round from existing backers, providing fresh capital for product integration and market expansion.

Led · Seed · Dec 2025

AILOS Robotics is a Brussels-based spin-off from the Vrije Universiteit Brussel and its BruBotics research centre that focuses on robotic actuation. After a decade of research supported by VLAIO and Innoviris, the team has commercialised its patented R2poweR gearbox, which blends quasi-direct drive agility with industry-leading torque density. The architecture enables lighter, quieter, more energy-efficient robots capable of safe human interaction, and is designed for cost-effective, scalable production suited to high-volume manufacturing. Having validated its minimum viable product, the company is now transitioning from lab to factory and engaging robot manufacturers for pilot integrations. Near-term plans include scaling manufacturing capacity and solidifying supply-chain partnerships to support Europe’s humanoid and collaborative robotics sectors. Financially, AILOS has secured a €3.5 million seed round to fund industrialisation; no revenue or deployment metrics have yet been disclosed.

Participated · Equity · Nov 2025

Innocens is a biotech spin-off from the University of Antwerp building an AI-based Clinical Decision Support System for neonatal intensive care units. The software delivers 24/7 risk predictions to help caregivers detect early signs of infections, sepsis, and other complications in premature or critically ill newborns. With its technology, the company aims to improve clinical outcomes and reduce the workload of NICU staff. The recently secured capital will fund a new clinical validation study and enable Innocens to obtain CE regulatory certification, both prerequisites for broader market entry. Management will also use the money to strengthen the team’s competencies and accelerate the commercial rollout across Europe. Although no operating revenue or user metrics are disclosed, the company completed an initial financing round in 2023 and views the latest capital injection as a bridge to full commercialization.